6 years ago

Sense Biodetection Secures €14 Million to Develop Instrument-Free Diagnostic Tests

  • Sense Biodetection, a Cambridge-based company, has raised €14 million to develop its instrument-free, point-of-care molecular diagnostic tests

  • The Series A funding was co-led by Cambridge Innovation Capital (CIC) and Earlybird, with participation from Jonathan Milner and seed round investor Mercia Asset Management

  • The company plans to use the funds to develop and manufacture a range of tests utilizing its novel, rapid molecular amplification technology, targeting infectious disease applications such as influenza

  • Sense's vision is to enable decentralised healthcare, allowing rapid tests for viral and bacterial pathogens to be performed within minutes in doctors' offices, pharmacies, or community facilities.

      • ProblemHealthcare

      "Existing molecular diagnostic tests often require specialized equipment and trained personnel, limiting their accessibility in point-of-care settings like doctors' offices and pharmacies."

      Solution

      "Sense Biodetection is developing instrument-free, rapid molecular diagnostic tests that provide lab-quality results within minutes, enabling point-of-care testing for various conditions, including infectious diseases."

      Covered on